Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective

Over the last decade, clinical trials using various poly ADP ribose polymerase (PARP) inhibitors on patients with ovarian cancer have shown promising results. The introduction of PARP inhibitors has changed the treatment landscape and improved outcomes for patients with ovarian cancer. Fuzuloparib,...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ning, Liu, Qi, Tian, Yu, Wu, Lingying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634097/
https://www.ncbi.nlm.nih.gov/pubmed/36335989
http://dx.doi.org/10.3802/jgo.2022.33.e86

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634097/
https://www.ncbi.nlm.nih.gov/pubmed/36335989
http://dx.doi.org/10.3802/jgo.2022.33.e86

Ejemplares similares